{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-25-000003","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.551166+00:00","generated_at":"2026-05-28T03:59:43.173056+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"QuidelOrtho expects Q4 2024 revenue of $702-707M, above guidance midpoint","bullets":["Preliminary total revenue $702-707M, in line with prior guidance; non-respiratory $561-563M, respiratory $141-143M.","CEO states 'positive note' and expects top-line above 2024 guidance midpoint; full results due Feb 12, 2025.","Company highlights cost-savings initiatives and leadership realignment during fiscal 2024.","Respiratory revenue ranges reflect lower Q4 demand compared to prior year; Labs segment also in line."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-25-000003","json":"https://secwatch.observer/filing/0001906324-25-000003.json","markdown":"https://secwatch.observer/filing/0001906324-25-000003.md","text":"https://secwatch.observer/filing/0001906324-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632425000003/0001906324-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632425000003/qdel-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:59:43.173056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}